Business
Update, Equity Issue and PDMR Notification
Genflow Biosciences Plc has terminated its previously announced initial transaction from October 2, 2025. Instead, the company has raised £440,000 before expenses through an alternative transaction. This involved allotting 40,000,000 new ordinary shares at a price of 1.1 pence each to Eric Leire. Leire will direct 35,454,546 of these shares to a consortium of existing shareholders, retaining the remaining 4,545,454 shares himself. Purchasers and Leire will also receive warrants on a one-for-one basis, exercisable at 1.2 pence for 24 months. Following admission, the total number of issued shares and voting rights will be 493,547,942. Admission to the FCA official list is expected around 8:00 a.m. on October 16, 2025. Disclaimer*
About this update from Genflow Biosciences Plc
[{"type":"text","content":"\n\n \nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n \n9 October 2025\n \nGenflow Biosciences Plc\n \nTermination of Initial Transaction, Subscription of New Ordinary Shares, Warrant Issue and PDMR Dealings\n \nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), announces that its board of directors has taken the decision to terminate, and not to proceed with, the subscription announced by the Company on 2 October 2025 (the \"Initial Transaction\"). Please see Issue of Equity - Correction - 12:37:10 02 Oct 2025 - GENF News article | London Stock Exchange.\n \nIn the alternative, it has raised gross proceeds of £440,000 (before expenses) via an allotment to Eric Leire of 40,000,000 new ordinary shares of £0.0003 each (\"New Ordinary Shares\") at an issue price of 1.1 pence (being the closing bid price as at close of business on 8 October 2025) (the \"Issue Price\") (the \"Alternative Transaction\"). \n \nThe Board has taken this decision on the basis that the Alternative Transaction is more favourable to, and less dilutive for, shareholders than the Initial Transaction.\n \nIssuance of the New Ordinary Shares\nThe Company continues to be unable to issue and admit the New Ordinary Shares without either the publication of a prospectus approved by the Financial Conduct Authority (\"FCA\") or relying upon an exemption to the requirement to issue a prospectus.\n \nConsequentially, the Alternative Transaction involves a subscription by Eric Leire, CEO and director of the Company, for the New Ordinary Shares at the Issue Price pursuant to the employee offer exemption under Article 1(4)(i) and 1(5) (h) of the UK Prospectus Regulation.\n \nFollowing allotment of the New Ordinary Shares, Eric Leire has agreed to direct the issue of 35,454,546 of such New Ordinary Shares to a consortium of existing shareholders (the \"Purchasers\"). Eric Leire will be issued the remaining 4,545,45...